BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+ at SITC 2025

• Next generation Bria-OTS+ platform demonstrates rapid, potent and durable anti-cancer activity by activating both innate and adaptive immune responses
• Increased tumor cell cytotoxicity induced by both Bria-BRES+ (breast cancer) and Bria-PROS+ (prostate cancer)
• Preclinical data reinforces broad potential of Bria-OTS+ platform across multiple indications
  

PHILADELPHIA and VANCOUVER, British Columbia, Nov. 07, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company is presenting evidence of strong immune system engagement and anti-cancer activity of its next generation Bria-OTS+ platform in preclinical models at a poster presentation at the Society for Immunotherapy of Cancer (SITC) 40^th Anniversary Annual Meeting, to be held November 7-9, 2025, in National Harbor, MD.

Title: Redefining Cancer Vaccines: Bria-OTS+ Integrates Trained Innate Immunity and Adaptive Memory to Overcome Immune Resistance
Abstract Number: 353
Location: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center
Date: Friday, November. 7, 2025
Time: 12:15-1:45 PM, and 5:35-7 PM ET

“We are thrilled with the comprehensive, powerful, and long-lasting immune activation demonstrated by Bria-OTS+ in our preclinical studies, which we believe will translate into meaningful anti-cancer immune responses in the clinic,” stated Miguel A. Lopez-Lago, PhD, BriaCell’s Chief Scientific Officer. “By training both the innate and adaptive arms of the immune system, Bria-OTS+ represents an important step toward developing more durable and broadly effective cancer immunotherapies.”

“These findings add to the growing body of evidence supporting our Bria-OTS+ platform’s unique mechanism of action for novel personalized cancer immunotherapies. We look forward to confirming these encouraging preclinical results in planned clinical trials of Bria-BRES+ for breast cancer and Bria-PROS+ for prostate cancer,” commented Dr. William V. Williams, BriaCell’s President and CEO.

Summary of Preclinical Findings

Bria-OTS+ Fast Acting and Potent Anti-Cancer Immune System Activation:
Bria-BRES+ and Bria-PROS+ rapidly activated key components of the immune system in preclinical models. The platform induced coordinated innate and adaptive immune responses, training the immune system to kill cancer cells. These findings are consistent with strong anti-tumor immune activity and support its promise as BriaCell’s next generation cancer immunotherapy platform.